MCID: PST046
MIFTS: 52

Post-Transplant Lymphoproliferative Disease

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

MalaCards integrated aliases for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 38 50 56
Post-Transplant Lymphoproliferative Disorder 69
Ptld 56

Characteristics:

Orphanet epidemiological data:

56
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

Orphanet 56 ORPHA70568
UMLS via Orphanet 70 C0432487
ICD10 via Orphanet 34 D47.9

Summaries for Post-Transplant Lymphoproliferative Disease

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to lymphoma and hepatitis b. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Benzocaine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 72 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.7 IL10 IL6 TNF TNFRSF10A
2 hepatitis b 30.2 B2M IL10 TNF
3 toxoplasmosis 30.2 IL6 LTA TNF
4 lyme disease 11.1
5 pure autonomic failure 10.8 IL10 TNF
6 acute ackee fruit intoxication 10.8 IL10 TNF
7 multiple familial trichoepithelioma 10.7 IL10 TNF
8 basidiobolomycosis 10.7 IL10 TNF
9 lagophthalmos 10.7 IL10 TNF
10 cardiac sarcoidosis 10.7 TNF TNFRSF1B
11 diabetic angiopathy 10.7 IL10 LTA
12 lung disease 10.7 TNF TNFRSF1B
13 prostate calculus 10.7 TNF TNFRSF10A
14 smarca4-deficient sarcoma of thorax 10.7 IL6 TNF
15 peroneal nerve paralysis 10.7 IL10 IL6
16 drug rash with eosinophilia and systemic symptoms 10.6 IL10 IL6
17 cerebellum cancer 10.6 TNF TNFRSF1B
18 neuromuscular disease 10.6 TNF TNFRSF1B
19 aortic arch interruption 10.6 IL6 TNF
20 microcephaly, short stature, and limb abnormalities 10.6 IL10 IL10RA
21 cryptococcosis 10.6 IL10 TNF TNFRSF1B
22 cutaneous leishmaniasis 10.6 IL6 TNF
23 solitary plasmacytoma of chest wall 10.6 B2M IL6
24 multiple epiphyseal dysplasia 10.6 TNF TNFRSF1A TNFRSF1B
25 multiple sclerosis 5 10.6 TNF TNFRSF1A TNFRSF1B
26 endosalpingiosis 10.6 IL10 TNF
27 discitis 10.6 TNF TNFRSF1A TNFRSF1B
28 bladder calculus 10.6 TNF TNFRSF1B
29 retinitis pigmentosa 75 10.6 TNF TNFRSF1A
30 lymph node palisaded myofibroblastoma 10.6 IL10 IL1A
31 peripheral nervous system disease 10.6 TNF TNFRSF1A TNFRSF1B
32 dermatosis papulosa nigra 10.5 TNF TNFRSF1B
33 type 1 papillary adenoma of the kidney 10.5 IL10 LTA TNF
34 choreatic disease 10.5 TNF TNFRSF1A TNFRSF1B
35 idiopathic dilatation of the pulmonary artery 10.5 IL10 LTA TNF
36 liver leiomyoma 10.5 IL10 LTA TNF
37 spondylocostal dysostosis 4 10.5 B2M LTA TNF
38 psoriasis susceptibility 1 10.5 TNF TNFRSF1A TNFRSF1B
39 benign eccrine breast spiradenoma 10.5 IL10 SLC11A1 TNF
40 crystal arthropathies 10.5 IL1R1 IL6
41 dengue disease 10.5 IL10 SLC11A1 TNF
42 mucocutaneous leishmaniasis 10.5 IL10 SLC11A1 TNF
43 tricho onychic dysplasia 10.5 IL10 IL6 TNF
44 phlyctenulosis 10.5 IL10 IL6 TNF
45 cyclosporiasis 10.5 IL10 IL6 TNF
46 early-onset zonular cataract 10.5 IL10 IL6 TNF
47 familial cold-induced inflammatory syndrome 1 10.5 IL1R1 TNFRSF1A
48 ulcerative colitis 10.5 IL10 IL6 TNF
49 morphine dependence 10.5 TNFRSF10A TNFRSF1B
50 hemophagocytic lymphohistiocytosis 10.5 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 TNFRSF1B TNFSF10 CASP8 FADD IL10 IL1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 TNFSF10 CASP8 FADD IL10 IL1A LTA

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 IL1A IL1R1 IL6 LTA SLC11A1 TNF
2 cardiovascular system MP:0005385 10.35 B2M CASP8 FADD IL10 IL1A IL1R1
3 immune system MP:0005387 10.35 B2M CASP8 FADD IL10 IL10RA IL1A
4 homeostasis/metabolism MP:0005376 10.34 IL1R1 IL6 LTA TNF TNFRSF10A TNFRSF1A
5 endocrine/exocrine gland MP:0005379 10.31 IL10 IL1R1 IL6 LTA TNF TNFRSF10A
6 cellular MP:0005384 10.3 TNFRSF1B B2M CASP8 FADD IL10 IL10RA
7 growth/size/body region MP:0005378 10.22 B2M CASP8 FADD IL10 IL1R1 IL6
8 mortality/aging MP:0010768 10.22 TNFRSF1B B2M CASP8 FADD IL10 IL1R1
9 digestive/alimentary MP:0005381 10.2 B2M FADD IL10 IL10RA IL6 SLC11A1
10 liver/biliary system MP:0005370 10.17 IL1R1 IL6 LTA TNF TNFRSF1A TNFRSF1B
11 integument MP:0010771 10.11 B2M CASP8 IL10 IL1A IL1R1 IL6
12 neoplasm MP:0002006 10.1 B2M CASP8 IL10 IL1A IL1R1 IL6
13 muscle MP:0005369 9.97 CASP8 FADD IL10 IL1R1 IL6 TNF
14 nervous system MP:0003631 9.96 B2M CASP8 FADD IL10 IL1R1 IL6
15 respiratory system MP:0005388 9.76 CASP8 IL10 IL1R1 IL6 LTA TNF
16 skeleton MP:0005390 9.61 FADD IL10 IL1R1 IL6 LTA TNF
17 vision/eye MP:0005391 9.17 IL10 IL1R1 IL6 LTA TNF TNFRSF1A

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
2
Everolimus Approved Phase 4,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
6
Pancrelipase Approved Phase 4 53608-75-6
7
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
10
Fludarabine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
11
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 174722-31-7 10201696
12
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2 23214-92-8 31703
13
Vidarabine Approved Phase 4,Phase 2,Phase 1 24356-66-9 32326 21704
14
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
15 tannic acid Approved, Nutraceutical Phase 4,Phase 2
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2 31703
17 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
19 Antifungal Agents Phase 4,Phase 2,Phase 1
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
22 Calcineurin Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 pancreatin Phase 4
26 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
28 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
33 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
34
Lenograstim Approved Phase 2, Phase 3, Phase 1 135968-09-1
35
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
36
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
37
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
38
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
39
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
41
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
42
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
43
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
46 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
47 Cyclosporins Phase 3,Phase 2,Phase 1
48 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
49 Adjuvants, Immunologic Phase 2, Phase 3
50 diuretics Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 190)

id Name Status NCT ID Phase Drugs
1 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4 Sirolimus;Tacrolimus
2 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
3 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
4 Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation Unknown status NCT00033475 Phase 3
5 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
6 Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
7 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed NCT00083551 Phase 3 Thalidomide;Ara-C;BCNU;Cisplatin;Cytoxan;Dexamethasone;Doxorubicin;Etoposide;Filgrastim;Recombinant GM-CSF;Interferon-alpha-2b;Melphalan;Vincristine
14 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
15 Maintenance Therapy Using Lenalidomide in Myeloma Active, not recruiting NCT00430365 Phase 3 lenalidomide;placebo
16 Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer Not yet recruiting NCT02999854 Phase 3 Cyclophosphamide
17 Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Unknown status NCT02007811 Phase 1, Phase 2
18 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
19 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
20 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
21 Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas Unknown status NCT02049580 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide
22 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
23 Risk Stratified Sequential Treatment for CD20-positive PTLD Completed NCT00590447 Phase 2 rituximab monotherapy;sequential R-CHOP
24 Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Completed NCT00307125 Phase 2 Rituximab plus immunosuppression;Placebo plus immunosuppression
25 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation Completed NCT01208337 Phase 2 Alemtuzumab
26 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
27 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
28 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
29 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2 Everolimus
30 Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Completed NCT00201240 Phase 2
31 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
32 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
33 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
34 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
35 Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant Completed NCT00303667 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate;Cyclosporin A;cyclophosphamide;fludarabine phosphate
36 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
37 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
38 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Completed NCT01036009 Phase 2
39 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Completed NCT01336712 Phase 2
40 Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00031642 Phase 1, Phase 2
41 Post Transplant Donor Lymphocyte Infusion Completed NCT00167180 Phase 2 Induction Chemotherapy
42 Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy Recruiting NCT02042391 Phase 2 Rituximab sc;Rituximab sc consolidation;Rituximab sc combined with CHOP chemotherapy;Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
43 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas Recruiting NCT02763254 Phase 2
44 A Study of the Safety and Efficacy of EBV Specific T-cell Lines Recruiting NCT02580539 Phase 1, Phase 2
45 Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma Recruiting NCT02753062 Phase 2 bendamustine, rituximab
46 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
47 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
48 Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia Recruiting NCT03104491 Phase 1, Phase 2 Inotuzumab Ozogamicin
49 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Recruiting NCT02996773 Phase 1, Phase 2 Bendamustine;Cyclophosphamide
50 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Recruiting NCT03192397 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Melphalan Hydrochloride;Mycophenolate Mofetil;Tacrolimus

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

39
T Cells, B Cells, Bone, Bone Marrow, Liver, Myeloid, Kidney

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 154)
id Title Authors Year
1
Post-transplant lymphoproliferative disease in liver transplant recipients. ( 28508661 )
2017
2
Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. ( 28383790 )
2017
3
Immunotherapy with the trifunctional anti-CD20a88A9a88anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. ( 28093004 )
2017
4
Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. ( 28780922 )
2017
5
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
6
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. ( 27467959 )
2016
7
The Role of Antiviral Prophylaxis for the Prevention of Epstein Barr Virus Associated Post-transplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. ( 27545492 )
2016
8
Persistent Epstein-Barr viral load in Epstein-Barr viral naA^ve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. ( 28058224 )
2016
9
Comment on: Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26944670 )
2016
10
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. ( 25686696 )
2015
11
Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. ( 25936966 )
2015
12
FDG-PET/CT in Abdominal Post-Transplant Lymphoproliferative Disease. ( 26544161 )
2015
13
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study. ( 26155195 )
2015
14
Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation: an evolving landscape. ( 26262461 )
2015
15
Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report. ( 26361705 )
2015
16
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26279197 )
2015
17
How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation? ( 26549285 )
2015
18
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. ( 25845981 )
2015
19
Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. ( 25843801 )
2015
20
Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge. ( 26239296 )
2015
21
Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals 'intact genomes' arguing against categorizing it as part of the post-transplant lymphoproliferative disease spectrum. ( 25041332 )
2014
22
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. ( 24399278 )
2014
23
CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. ( 25242095 )
2014
24
Epistaxis in a kidney transplant recipient: an uncommon presentation of post-transplant lymphoproliferative disease. ( 23577919 )
2013
25
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. ( 23737188 )
2013
26
Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. ( 24335998 )
2013
27
Isolated post-transplantation lymphoproliferative disease involving the breast and axilla as peripheral T-cell lymphoma. ( 24043963 )
2013
28
Breast involvement with post-transplant lymphoproliferative disease in a renal transplant recipient. ( 24034058 )
2013
29
Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. ( 24056821 )
2013
30
Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. ( 23802715 )
2013
31
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. ( 22711849 )
2012
32
Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. ( 23498038 )
2012
33
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. ( 22801669 )
2012
34
Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. ( 22554096 )
2012
35
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. ( 21584931 )
2012
36
Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm. ( 22915052 )
2012
37
CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. ( 21559814 )
2011
38
Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. ( 21518001 )
2011
39
Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. ( 21056103 )
2011
40
Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C. ( 21555941 )
2011
41
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). ( 21294246 )
2011
42
CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. ( 21275950 )
2011
43
Tonsillectomy in post-transplant lymphoproliferative disease in children. ( 20131364 )
2010
44
Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. ( 20345506 )
2010
45
The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. ( 20070559 )
2010
46
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). ( 20493424 )
2010
47
Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. ( 19497070 )
2009
48
Post-transplant lymphoproliferative disease. ( 17891420 )
2009
49
Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring. ( 19017289 )
2009
50
Post-transplant lymphoproliferative disease presenting as a mass in the left ventricle in a heart transplant recipient at long-term follow-up. ( 19201350 )
2009

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 B2M CASP8 FADD IL10 IL10RA IL1A
2
Show member pathways
13.87 CASP8 FADD IL6 LTA TNF TNFRSF10A
3
Show member pathways
13.85 CASP8 FADD IL10 IL10RA IL1A IL1R1
4
Show member pathways
13.64 CASP8 IL10 IL10RA IL1A IL1R1 IL6
5
Show member pathways
13.56 IL10 IL10RA IL1A IL1R1 IL6 LTA
6
Show member pathways
13.4 B2M IL10 IL10RA IL1A IL1R1 IL6
7
Show member pathways
13.33 FADD IL10 IL10RA IL1A IL1R1 IL6
8
Show member pathways
13.1 CASP8 IL10 IL10RA IL1A IL1R1 IL6
9
Show member pathways
13.03 CASP8 FADD IL1A IL1R1 IL6 TNF
10
Show member pathways
12.94 CASP8 FADD IL6 TNF TNFRSF10A TNFRSF1A
11
Show member pathways
12.93 CASP8 FADD IL10 IL6 TNF TNFRSF1A
12
Show member pathways
12.92 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
13
Show member pathways
12.92 B2M CASP8 FADD IL10 IL1A IL6
14
Show member pathways
12.82 IL6 LTA TNF TNFRSF1A TNFRSF1B
15
Show member pathways
12.82 CASP8 FADD IL1R1 LTA TNF TNFRSF10A
16
Show member pathways
12.81 CASP8 FADD IL1R1 TNFRSF10A TNFSF10
17
Show member pathways
12.78 CASP8 FADD IL1A IL6 LTA TNF
18
Show member pathways
12.77 FADD IL1A IL1R1 IL6 LTA TNF
19 12.76 CASP8 IL1A IL1R1 TNF TNFRSF1A
20
Show member pathways
12.73 IL1A IL1R1 LTA TNF TNFRSF1A TNFRSF1B
21 12.68 CASP8 FADD IL6 TNF TNFRSF1A
22
Show member pathways
12.68 IL10 IL10RA TNF TNFRSF1A TNFRSF1B
23
Show member pathways
12.65 IL10 IL1A IL1R1 IL6 TNF
24 12.6 B2M IL10 TNF TNFRSF1A TNFRSF1B
25
Show member pathways
12.59 IL10 IL10RA IL6 TNF
26 12.5 IL1R1 IL6 LTA TNF TNFRSF1A
27
Show member pathways
12.46 IL10 IL1A IL6 TNF
28
Show member pathways
12.39 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
29
Show member pathways
12.37 CASP8 FADD IL6 TNF
30
Show member pathways
12.36 CASP8 IL10 IL10RA IL1A TNF TNFRSF1A
31
Show member pathways
12.34 CASP8 FADD TNFRSF10A TNFSF10
32 12.34 CASP8 FADD TNFRSF10A TNFRSF1A TNFRSF1B TNFSF10
33
Show member pathways
12.33 CASP8 FADD IL1A TNF TNFRSF1A
34
Show member pathways
12.32 IL1A IL1R1 IL6 TNF
35
Show member pathways
12.25 IL10 IL1A IL6 LTA TNF
36 12.23 IL10 IL1A IL6 TNF
37
Show member pathways
12.18 CASP8 FADD TNF TNFRSF1A
38
Show member pathways
12.18 CASP8 FADD IL1A IL1R1 LTA TNF
39 12.15 IL1A IL1R1 TNF TNFRSF1A
40 12.11 IL1A IL1R1 TNF TNFRSF1A
41
Show member pathways
12.09 CASP8 FADD TNF TNFRSF1A
42 12.09 IL10 IL1A IL6 TNF TNFRSF1B
43 12.08 IL1A IL1R1 IL6 TNF
44
Show member pathways
12.03 CASP8 IL1A IL1R1
45
Show member pathways
12.02 IL10 IL6 LTA TNF
46 12.01 CASP8 FADD IL10 IL10RA IL1A IL6
47 12 IL10 IL6 TNF
48
Show member pathways
11.99 TNF TNFRSF1A TNFRSF1B
49 11.98 IL1A IL1R1 IL6 TNF
50
Show member pathways
11.97 IL6 TNF TNFRSF1A

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 IL1R1 SLC11A1 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 cell surface GO:0009986 9.83 B2M IL1R1 TNF TNFRSF10A TNFRSF1A
3 extracellular space GO:0005615 9.76 B2M IL10 IL1A IL6 LTA TNF
4 death-inducing signaling complex GO:0031264 9.37 CASP8 FADD
5 membrane raft GO:0045121 9.35 CASP8 FADD TNF TNFRSF1A TNFRSF1B
6 ripoptosome GO:0097342 9.32 CASP8 FADD
7 extracellular region GO:0005576 9.32 B2M IL10 IL1A IL1R1 IL6 LTA
8 CD95 death-inducing signaling complex GO:0031265 9.26 CASP8 FADD

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.98 IL10 SLC11A1 TNF TNFRSF1A
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 CASP8 FADD TNF TNFRSF1A TNFSF10
3 cytokine-mediated signaling pathway GO:0019221 9.96 IL10RA IL1A IL1R1 IL6 TNFRSF1A
4 cell surface receptor signaling pathway GO:0007166 9.95 CASP8 FADD IL1R1 TNFRSF10A TNFRSF1A TNFRSF1B
5 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 IL6 TNF TNFRSF1B
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.93 LTA TNF TNFRSF10A TNFRSF1A TNFRSF1B
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.9 IL10 IL6 TNF
8 defense response to Gram-positive bacterium GO:0050830 9.89 IL6 LTA TNF
9 cellular response to mechanical stimulus GO:0071260 9.89 CASP8 FADD TNFRSF10A TNFRSF1A
10 negative regulation of inflammatory response GO:0050728 9.88 IL10 TNFRSF1A TNFRSF1B
11 apoptotic signaling pathway GO:0097190 9.88 CASP8 FADD TNF TNFRSF1B
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 CASP8 FADD TNF TNFRSF10A TNFSF10
13 response to insulin GO:0032868 9.86 IL10 IL6 TNFSF10
14 response to glucocorticoid GO:0051384 9.86 IL10 IL6 TNF
15 inflammatory response GO:0006954 9.86 IL10 IL1A IL6 SLC11A1 TNF TNFRSF10A
16 positive regulation of interferon-gamma production GO:0032729 9.85 FADD LTA SLC11A1 TNF
17 humoral immune response GO:0006959 9.84 IL6 LTA TNF
18 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.84 TNF TNFRSF1A TNFRSF1B
19 positive regulation of interleukin-6 production GO:0032755 9.83 IL1A IL6 TNF
20 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.83 CASP8 FADD TNFRSF10A TNFSF10
21 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.81 FADD TNF TNFRSF10A TNFRSF1A
22 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.8 CASP8 TNF TNFRSF1A
23 positive regulation of cytokine secretion GO:0050715 9.79 IL10 IL1A TNF
24 defense response to protozoan GO:0042832 9.78 IL10 IL6 SLC11A1
25 negative regulation of growth of symbiont in host GO:0044130 9.76 IL10 LTA TNF
26 positive regulation of proteolysis GO:0045862 9.73 CASP8 FADD
27 positive regulation of chemokine production GO:0032722 9.73 IL6 TNF
28 lymph node development GO:0048535 9.73 FADD LTA
29 iron ion transport GO:0006826 9.73 B2M SLC11A1
30 interleukin-1-mediated signaling pathway GO:0070498 9.73 IL1A IL1R1
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNF TNFRSF1B
32 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.73 CASP8 FADD TNFRSF10A TNFSF10
33 cellular response to hepatocyte growth factor stimulus GO:0035729 9.72 IL10 IL6
34 positive regulation of macrophage differentiation GO:0045651 9.72 CASP8 FADD
35 response to molecule of bacterial origin GO:0002237 9.72 B2M IL10
36 extrinsic apoptotic signaling pathway GO:0097191 9.72 CASP8 FADD TNF TNFRSF10A TNFRSF1B
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
38 regulation of necroptotic process GO:0060544 9.71 CASP8 FADD
39 positive regulation of T cell mediated cytotoxicity GO:0001916 9.71 B2M FADD
40 activation of cysteine-type endopeptidase activity GO:0097202 9.7 CASP8 FADD
41 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
42 positive regulation of ceramide biosynthetic process GO:2000304 9.7 TNF TNFRSF1A
43 regulation of synapse organization GO:0050807 9.69 IL10 IL10RA
44 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
45 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF TNFRSF1A
46 necroptotic signaling pathway GO:0097527 9.68 FADD TNF
47 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
48 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.67 IL6 TNF
49 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.67 CASP8 FADD TNFRSF10A TNFSF10
50 positive regulation of neutrophil extravasation GO:2000391 9.65 IL1A IL1R1

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.71 B2M CASP8 FADD TNF
2 protease binding GO:0002020 9.56 FADD IL1R1 TNF TNFRSF10A
3 death receptor binding GO:0005123 9.46 CASP8 FADD
4 cytokine activity GO:0005125 9.43 IL10 IL1A IL6 LTA TNF TNFSF10
5 tumor necrosis factor receptor superfamily binding GO:0032813 9.37 FADD TNFSF10
6 tumor necrosis factor-activated receptor activity GO:0005031 9.33 TNFRSF10A TNFRSF1A TNFRSF1B
7 death effector domain binding GO:0035877 9.32 CASP8 FADD
8 tumor necrosis factor receptor binding GO:0005164 9.02 CASP8 FADD LTA TNF TNFSF10
9 protein binding GO:0005515 10.25 B2M CASP8 FADD IL10 IL10RA IL1A

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....